252
Participants
Start Date
April 25, 2022
Primary Completion Date
February 15, 2025
Study Completion Date
August 15, 2025
PTC518
PTC518 will be administered per dose and schedule specified in the arm.
Placebo
Placebo matching to PTC518 will be administered per schedule specified in the arm.
Westmead Hospital, Sydney
Monash Health, Clayton
Medical University Innsbruck, Innsbruck
University of Otago, New Zealand Brain Research Institute, Christchurch
Hospital de la Santa Creu I Sant Pau, Barcelona
Charite University Medicine Berlin, Berlin
Hôpital Universitaire de Marseille Hôpital de la Timone, Marseille
IRCCS Carlo Besta Neurological Institutte, Milan
Hospital Ramón y Cajal, Madrid
Vanderbilt University Medical Center, Nashville
Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica, Bologna
Ruhr-Univ. Bochum St. Joseph-Hospital, Bochum
George-Huntington-Institut, Münster
Hospital Universitario Cruces, Barakaldo
Centre Hospitalier Universitaire d'Angers, Angers
IRCCS Casa Sollievo della Sofferenza Research Hospital, San Giovanni Rotondo
Brain and Spine Institute Paris, Paris
The University of Texas Health Science Center at Houston; McGovern Medical School, Houston
Ulm University, UKU, Dep. of Neurology, Ulm
Hospital Universitario Burgos, Burgos
University of California, San Diego, La Jolla
University of Washington Department of Neurology, Seattle
The Ottawa Hospital, Parkinson's and Movement Disorders Clinic, Ottawa
Leiden University Medical Center, Leiden
The Barbery National Centre for Mental Health, Birmingham
Cardiff University Schools of Medicine and Biosciences, Cardiff
UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery, London
Manchester University NHS Foundation Trust, Manchester
Lead Sponsor
PTC Therapeutics
INDUSTRY